EMEA-002981-PIP01-21
Key facts
| Active substance |
2'-O-(2-methoxyethyl) phosphorothioate antisense oligonucleotide targeting CD49d RNA (ATL1102)
|
| Therapeutic area |
Other
|
| Decision number |
P/0504/2021
|
| PIP number |
EMEA-002981-PIP01-21
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of Duchenne muscular dystrophy
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Antisense Therapeutics Limited
Email: Nuket.Desem@Antisense.com.au |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|